Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM, a rare, life-threatening neuromuscular disease, affecting about 1 in 40-50,000 newborn males. The session will review how IPM.ai and Audentes collaborated to uncover the XLMTM patient population, with the objectives of:
- Discovering the known and undiagnosed patient population
- Mapping the patient journey for confirmed XLMTM patients
- Examining frequent concomitant or misdiagnosed clinical events
- Identifying opportunities to shorten the diagnostic journey
Our conversation will speak directly to biopharma manufacturers who are developing a therapy in rare or specialty diseases markets, including those involved in business analytics, drug development, clinical operations, new drug commercialization, and brand marketing.